Ana Navas-Acien, Regina M Santella, Bonnie R Joubert, Zhen Huang, Yuliya Lokhnygina, Francisco Ujueta, Irina Gurvich, Nancy J LoIacono, Filippo Ravalli, Cynthia D Ward, Jeffery M Jarrett, Alfonsina De Leon Salazar, Robin Boineau, Teresa L Z Jones, Daniel B Mark, Jonathan D Newman, David M Nathan, Kevin J Anstrom, Gervasio A Lamas
BACKGROUND: The reduction in cardiovascular disease (CVD) events with edetate disodium (EDTA) in the Trial to Assess Chelation Therapy (TACT) suggested that chelation of toxic metals might provide novel opportunities to reduce CVD in patients with diabetes. Lead and cadmium are vasculotoxic metals chelated by EDTA. We present baseline characteristics for participants in TACT2, a randomized, double-masked, placebo-controlled trial designed as a replication of the TACT trial limited to patients with diabetes...
April 13, 2024: American Heart Journal